|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ANO9 |
Gene summary for ANO9 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ANO9 | Gene ID | 338440 |
| Gene name | anoctamin 9 | |
| Gene Alias | PIG5 | |
| Cytomap | 11p15.5 | |
| Gene Type | protein-coding | GO ID | GO:0006810 | UniProtAcc | A1A5B4 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 338440 | ANO9 | HTA11_3410_2000001011 | Human | Colorectum | AD | 4.40e-02 | -8.79e-02 | 0.0155 |
| 338440 | ANO9 | HTA11_2487_2000001011 | Human | Colorectum | SER | 4.29e-09 | 5.61e-01 | -0.1808 |
| 338440 | ANO9 | HTA11_347_2000001011 | Human | Colorectum | AD | 5.63e-04 | 2.58e-01 | -0.1954 |
| 338440 | ANO9 | HTA11_3361_2000001011 | Human | Colorectum | AD | 2.17e-03 | 4.21e-01 | -0.1207 |
| 338440 | ANO9 | HTA11_1391_2000001011 | Human | Colorectum | AD | 1.55e-05 | 4.26e-01 | -0.059 |
| 338440 | ANO9 | HTA11_99999971662_82457 | Human | Colorectum | MSS | 4.85e-05 | 4.10e-01 | 0.3859 |
| 338440 | ANO9 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 2.60e-03 | 3.44e-01 | 0.3005 |
| 338440 | ANO9 | A015-C-203 | Human | Colorectum | FAP | 3.67e-14 | 3.06e-01 | -0.1294 |
| 338440 | ANO9 | A002-C-201 | Human | Colorectum | FAP | 1.57e-04 | 2.78e-01 | 0.0324 |
| 338440 | ANO9 | A001-C-108 | Human | Colorectum | FAP | 1.84e-03 | 2.07e-02 | -0.0272 |
| 338440 | ANO9 | A002-C-205 | Human | Colorectum | FAP | 8.11e-06 | 1.41e-01 | -0.1236 |
| 338440 | ANO9 | A015-C-006 | Human | Colorectum | FAP | 4.76e-13 | 5.19e-01 | -0.0994 |
| 338440 | ANO9 | A015-C-106 | Human | Colorectum | FAP | 8.71e-04 | 1.70e-01 | -0.0511 |
| 338440 | ANO9 | A002-C-114 | Human | Colorectum | FAP | 1.05e-04 | 1.11e-01 | -0.1561 |
| 338440 | ANO9 | A015-C-104 | Human | Colorectum | FAP | 1.87e-20 | 3.66e-01 | -0.1899 |
| 338440 | ANO9 | A015-C-202 | Human | Colorectum | FAP | 7.49e-03 | 3.00e-01 | -0.0849 |
| 338440 | ANO9 | A001-C-014 | Human | Colorectum | FAP | 1.12e-02 | -8.91e-02 | 0.0135 |
| 338440 | ANO9 | A002-C-016 | Human | Colorectum | FAP | 2.82e-06 | -2.08e-01 | 0.0521 |
| 338440 | ANO9 | A015-C-002 | Human | Colorectum | FAP | 2.13e-02 | 1.66e-01 | -0.0763 |
| 338440 | ANO9 | A002-C-116 | Human | Colorectum | FAP | 8.50e-11 | -2.35e-01 | -0.0452 |
| Page: 1 2 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0010876 | Colorectum | AD | lipid localization | 120/3918 | 448/18723 | 1.59e-03 | 1.33e-02 | 120 |
| GO:0006869 | Colorectum | AD | lipid transport | 108/3918 | 398/18723 | 1.67e-03 | 1.39e-02 | 108 |
| GO:0015698 | Colorectum | AD | inorganic anion transport | 52/3918 | 180/18723 | 6.83e-03 | 4.22e-02 | 52 |
| GO:0015748 | Colorectum | AD | organophosphate ester transport | 42/3918 | 140/18723 | 7.04e-03 | 4.31e-02 | 42 |
| GO:0051051 | Colorectum | SER | negative regulation of transport | 98/2897 | 470/18723 | 1.01e-03 | 1.19e-02 | 98 |
| GO:0007009 | Colorectum | SER | plasma membrane organization | 36/2897 | 142/18723 | 1.50e-03 | 1.62e-02 | 36 |
| GO:0032409 | Colorectum | SER | regulation of transporter activity | 65/2897 | 310/18723 | 5.71e-03 | 4.19e-02 | 65 |
| GO:00324091 | Colorectum | MSS | regulation of transporter activity | 78/3467 | 310/18723 | 2.09e-03 | 1.78e-02 | 78 |
| GO:0022898 | Colorectum | MSS | regulation of transmembrane transporter activity | 70/3467 | 278/18723 | 3.36e-03 | 2.54e-02 | 70 |
| GO:00510511 | Colorectum | MSS | negative regulation of transport | 110/3467 | 470/18723 | 4.20e-03 | 3.04e-02 | 110 |
| GO:0032412 | Colorectum | MSS | regulation of ion transmembrane transporter activity | 66/3467 | 267/18723 | 6.72e-03 | 4.38e-02 | 66 |
| GO:00108761 | Colorectum | MSS | lipid localization | 104/3467 | 448/18723 | 6.76e-03 | 4.38e-02 | 104 |
| GO:00228981 | Colorectum | FAP | regulation of transmembrane transporter activity | 62/2622 | 278/18723 | 1.09e-04 | 1.80e-03 | 62 |
| GO:00324121 | Colorectum | FAP | regulation of ion transmembrane transporter activity | 60/2622 | 267/18723 | 1.12e-04 | 1.84e-03 | 60 |
| GO:00324092 | Colorectum | FAP | regulation of transporter activity | 67/2622 | 310/18723 | 1.59e-04 | 2.43e-03 | 67 |
| GO:00068691 | Colorectum | FAP | lipid transport | 81/2622 | 398/18723 | 2.84e-04 | 3.76e-03 | 81 |
| GO:00510512 | Colorectum | FAP | negative regulation of transport | 91/2622 | 470/18723 | 7.09e-04 | 7.64e-03 | 91 |
| GO:00108762 | Colorectum | FAP | lipid localization | 85/2622 | 448/18723 | 1.92e-03 | 1.63e-02 | 85 |
| GO:00156981 | Colorectum | FAP | inorganic anion transport | 38/2622 | 180/18723 | 5.73e-03 | 3.67e-02 | 38 |
| GO:0015914 | Colorectum | FAP | phospholipid transport | 23/2622 | 96/18723 | 6.09e-03 | 3.82e-02 | 23 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ANO9 | SNV | Missense_Mutation | c.919G>A | p.Glu307Lys | p.E307K | A1A5B4 | protein_coding | deleterious(0.01) | probably_damaging(0.997) | TCGA-AC-A3BB-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | CR | |
| ANO9 | SNV | Missense_Mutation | novel | c.914N>T | p.Gln305Leu | p.Q305L | A1A5B4 | protein_coding | deleterious(0.01) | benign(0.169) | TCGA-AN-A0XN-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| ANO9 | SNV | Missense_Mutation | c.721N>C | p.Asp241His | p.D241H | A1A5B4 | protein_coding | deleterious(0.04) | benign(0.221) | TCGA-B6-A0RT-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
| ANO9 | SNV | Missense_Mutation | rs373327405 | c.2051N>A | p.Arg684His | p.R684H | A1A5B4 | protein_coding | deleterious(0.01) | probably_damaging(0.979) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| ANO9 | SNV | Missense_Mutation | rs754169194 | c.1999N>A | p.Asp667Asn | p.D667N | A1A5B4 | protein_coding | tolerated(0.56) | benign(0.005) | TCGA-E9-A1R4-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | 5-fluorouracil | SD |
| ANO9 | deletion | Frame_Shift_Del | novel | c.1286_1290delNNNNN | p.Phe429TyrfsTer192 | p.F429Yfs*192 | A1A5B4 | protein_coding | TCGA-AN-A0XU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| ANO9 | deletion | Frame_Shift_Del | novel | c.978delC | p.Tyr327ThrfsTer10 | p.Y327Tfs*10 | A1A5B4 | protein_coding | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD | ||
| ANO9 | SNV | Missense_Mutation | novel | c.986N>A | p.Arg329His | p.R329H | A1A5B4 | protein_coding | tolerated(0.06) | benign(0.099) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| ANO9 | SNV | Missense_Mutation | novel | c.404N>A | p.Gly135Asp | p.G135D | A1A5B4 | protein_coding | tolerated(0.22) | benign(0.22) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| ANO9 | SNV | Missense_Mutation | c.292G>A | p.Glu98Lys | p.E98K | A1A5B4 | protein_coding | tolerated(0.05) | benign(0.073) | TCGA-BI-A0VR-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |